Alecensa can only be obtained with a prescription and treatment must be started and supervised by a doctor who is experienced in using cancer medicines. Genetic defects affecting ALK (\u2018ALK-positive\u2019 status) should be confirmed in advance by appropriate methods.<\/p>\n
The medicine is available as capsules (150 mg). The recommended usual dose is 4 capsules taken twice a day with food (1,200 mg in total). For patients with severe liver impairment the recommended dose is 3 capsules taken twice a day with food (900 mg in total). The doctor may reduce the dose or stop treatment temporarily if side effects occur. In certain cases treatment should be permanently stopped.<\/p>\n
For more information about using Alecensa, see the\u00a0package leaflet<\/a>\u00a0or contact your doctor or pharmacist.<\/p>\n To access alectinib capsules sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Alectinib is prescribed for the treatment of a certain type (anaplastic lymphoma kinase (ALK)-positive) of non-small cell lung cancer that has spread to other parts of the body. It belongs to a group of medicines known as kinase Inhibitors given for patients who cannot take another drug, crizotinib, or in those in whom crizotinib was ineffective.<\/p>\n Disease Indications-Lung Cancer If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import alectinib capsules\u201d based on the information you provide.<\/strong><\/p>\nHow can 1 go about obtainingalectinib capsules?<\/h3>\n
ALECENSA (alectinib) capsules, for oral use Initial U.S. Approval: 2015<\/h5>\n","protected":false},"excerpt":{"rendered":"
alectinib capsules,
\nfor oral use Initial U.S. Approval: 2015<\/h2>\nFacts about alectinib capsules<\/h4>\n
\nManufacturer-Roche Registration GmbH
\nUsage-Oral
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Pharmaceuticals and Medical Devices Agency (PMDA), \u00a0Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n